Approximately 15-40% of all cancers develop metastases in the central nervous system (CNS), yet few therapeutic options exist to treat them. Cancer therapies based on monoclonal antibodies are widely successful, yet have limited efficacy against CNS metastases, owing to the low levels of the drug reaching the tumour site. Here, we show that the encapsulation of rituximab within a crosslinked zwitterionic polymer layer leads to the sustained release of rituximab as the crosslinkers are gradually hydrolysed, enhancing the CNS levels of the antibody by approximately tenfold with respect to the administration of naked rituximab. When the nanocapsules were functionalized with CXCL13-the ligand for the chemokine receptor CXCR5, which is frequently found on B-cell lymphoma-a single dose led to improved control of CXCR5-expressing metastases in a murine xenograft model of non-Hodgkin lymphoma, and eliminated lymphoma in a xenografted humanized bone marrow-liver-thymus mouse model. Encapsulation and molecular targeting of therapeutic antibodies could become an option for the treatment of cancers with CNS metastases.
T reatments for cancer metastases-especially those of the central nervous system (CNS)-are less successful than those for primary tumours 1 . Approximately 15-40% of all cancers develop a CNS metastasis 2, 3 , which most commonly arises from lung cancer, melanoma, breast cancer and colorectal cancer. Therapeutic monoclonal antibodies (mAbs) have revolutionized the treatment of cancer; however, their efficacy is limited in patients with CNS metastases due to insufficient mAb CNS delivery-typically 0.1% of the levels in plasma 4 . By bypassing the blood-brain barrier (BBB) through intrathecal or intraventricular administration, mAb therapy has shown some effectiveness against CNS tumour metastases [4] [5] [6] [7] [8] [9] [10] . However, direct CNS administration is invasive, with the potential for neurotoxicity, and is limited by rapid efflux of antibodies from the CNS within hours 5, 10, 11 . Therefore, novel approaches for mAb delivery are preferable to maintain systemic therapeutic effects in the CNS with improved efficiency.
To date, various carrier vehicles for macromolecule delivery, such as viral vectors, liposomes, cationic polymers, inorganic delivery systems and other biomolecules, have been explored to improve CNS delivery [12] [13] [14] . Viral vectors are effective for CNS delivery in some settings, but have potential safety concerns 15, 16 . Liposome-based protein delivery has been shown to penetrate the BBB, but with relatively low efficiency, biocompatibility and stability 17, 18 . Polymer nanoparticles conjugated to target ligands with a variety of structures and morphologies have been used to form micelles through self-assembly, but in vivo instability, tissue-specific accumulations and protein denaturation during complexing are problematic 19, 20 . Inorganic delivery systems, including gold nanoparticles 21, 22 and mesoporous silica particles 23 , are non-biodegradable and difficult to load or conjugate with macromolecules. Biomolecules, such as cellpenetrating peptides and antibodies, have improved the efficacy of macromolecule delivery, but degradation of cargo still hampers their therapeutic applications 24 . The above approaches have shown promise, but drastic improvements are needed-especially in the systemic delivery of macromolecules into the CNS 19, 25 . Rituximab (RTX) for the treatment of non-Hodgkin lymphoma (NHL) was the first anti-cancer antibody approved by the US Food and Drug Administration. RTX binds to CD20
+ lymphoma cells and induces cell death through complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis 26 . RTX may also promote anti-lymphoma immune responses 27 . The substantial benefits of RTX administration in Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice Articles NAtuRE BiomEdiCAL ENgiNEERiNg treatments for systemic NHL are well established, but treatment of primary and relapsed CNS lymphoma has not been effective through the intravenous route, probably due to the very low levels of systemic RTX entering the CNS 4 . CNS involvement in NHL is relatively rare, but there is elevated risk in patients with immunodeficiency diseases 9 or renal, cardiac, lung and liver transplants. We demonstrate that, compared with the administration of native RTX, timed-release nanocapsule delivery of RTX achieves around tenfold higher RTX concentrations in the CNS following a single-course treatment and is maintained for at least 4 weeks, as opposed to 1 week with native RTX. Furthermore, we developed a human NHL xenograft murine model for CNS metastases and show therapeutic efficacy of RTX nanocapsules against CNS lymphomas. In addition, using a humanized bone marrow-liver-thymus (BLT) mouse model, we demonstrate the clearance of CNS lymphomas.
results and discussion
Nanocapsules facilitate CNS penetration. We have developed a nanotechnology strategy whereby individual macromolecules are encapsulated within a thin polymer shell formed by in situ polymerization of monomers and stabilized by environmentally responsive crosslinkers 28, 29 . Like a virion capsid, the polymer shell shields cargo from the environment and confers high resistance to denaturation, proteases and nucleases, and determines the Brain P < 0.001 P < 0.001 P < 0.001 P = 0.0760 P = 0.1772 P = 0.0473 P < 0.001 P < 0.001 P < 0.001 + + Fig. 1 | timed-release nanocapsules facilitate brain delivery of rtX in mice. a, Schematic of the synthesis and release of timed-release RTX nanocapsules by: (1) enriching MPC monomers, hydrolysable crosslinker PLA-PEG-PLA and slowly hydrolysable crosslinker GDMA around an RTX molecule; (2) in situ polymerization of the monomer and crosslinkers, forming a thin shell of polymer around the RTX molecule; and (3) releasing RTX when polymer shells are degraded under physiological conditions by hydrolysis of the crosslinkers. b, RTX nanocapsules were synthesized with the mixed crosslinkers GDMA and PLA-PEG-PLA at ratios of PLA-PEG-PLA of 100, 50, 30 and 10%. Then, 25 µg of each nano-encapsulated RTX or native RTX (RTX) was added to 1 ml PBS and incubated at 37 °C for 1 week. The concentration of free RTX was measured by ELISA. c, The release rates of RTX nanocapsules with 50% PLA-PEG-PLA crosslinkers were compared in PBS buffers with various pH values representing physiological conditions (pH = 7.4 and 7.0) and acidic conditions (pH = 6.5, 6.0 and 5.5). A total of 25 µg of each sample was added to 1 ml PBS buffer and incubated at 37 °C for up to 1 week. The concentration of free RTX was measured by ELISA. Data are shown as means ± s.d. of biological duplicates. Statistical significance, compared with physiological conditions (pH 7.4), was calculated by one-tailed paired t-test with Welch's correction. d,e, B6 mice (n = 3) were administered 20 mg kg −1 native RTX or RTX nanocapsules with 50% PLA-PEG-PLA crosslinkers (n-RTX) via the retro-orbital vein. Plasma and CSF samples (b), as well as perfused brain tissue samples (c), were collected, and the concentrations of free RTX were measured by ELISA on days 1, 7 and 28. Data are shown as means ± s.d. of biological triplicates. Statistical significance, compared with the native RTX group, was determined by one-tailed unpaired t-test with Welch's correction.
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NAtuRE BiomEdiCAL ENgiNEERiNg distribution of nanocapsules. Nanocapsules with polymer shells formed by neutral monomers with zwitterionic properties (that is, 2-methacryloyloxyethyl phosphorylcholine (MPC)) exhibited broad biodistribution 30 and a long half-life 31 . MPC is used in contact lenses and has been tested for use in coronary stents and other medical devices 32, 33 . It is inert, highly stable and resistant to protein adsorption, and lacks immunogenicity. We synthesized RTX nanocapsules with MPC monomers and glycerol dimethacrylate (GDMA) crosslinkers (termed n-RTX (GDMA) ), which are efficiently degraded under acidic conditions but deteriorate very slowly under physiological conditions.
We first evaluated the biodistribution and brain delivery efficiency of our nanoparticles without release of the RTX cargo under physiological conditions using n-RTX (GDMA) (Supplementary Fig. 1 ). The biodistribution of the nanocapsules was assayed by enzymelinked immunosorbent assay (ELISA) after releasing RTX by acid treatment (pH 5.4) at 4 °C overnight ex vivo. Higher levels of n-RTX (GDMA) were present in the plasma by day 7. Importantly, more RTX released from n-RTX (GDMA) was observed in the brain and cerebrospinal fluid (CSF). The levels of released RTX in the CSF were 1.7-5.5% higher than the levels in the plasma (5.5% on day 1, 1.7% on day 7 and 3% on day 21); native RTX was undetectable in the CSF at all three points. This is consistent with the relative inability of antibodies to cross the BBB 4 . To achieve proper release of mAbs for therapeutic treatment, nanocapsules were designed to release cargo over time. This was accomplished by securing the polymer shell with mixed crosslinkers that were hydrolysed gradually under physiological conditions (Fig. 1a) . MPC monomers were enriched around the surface of individual RTX molecules through electrostatic interactions, then hydrolysable crosslinker (poly(d,l-lactide)-b-poly(ethylene glycol)-b-poly(d,l-lactide)-diacrylate triblock copolymers (PLA-PEG-PLA) and slowly hydrolysable crosslinker GDMA were associated by hydrogen bonding under physiological conditions. Subsequent polymerization in an aqueous solution wrapped each molecule with a thin shell of polymer through in situ free-radical polymerization. When PLA-PEG-PLA was hydrolysed by body fluids, the nanocapsules dissociated and released encapsulated RTX. These nanocapsules had a relatively uniform, small diameter of 20-30 nm, as measured by transmission electron microscopy ( Supplementary  Fig. 2) , and consisted of a single RTX molecule core-shell structure ( Supplementary Fig. 3 ). To sustain timed release in the plasma at a neutral pH, we mixed GDMA with PLA-PEG-PLA to achieve different release rates. Depending on the relative ratios of PLA-PEG-PLA (100, 50, 30 or 10%), these nanocapsules released RTX at different rates under physiological conditions (Fig. 1b) : RTX nanocapsules with 50% PLA-PEG-PLA crosslinker (termed n-RTX) enabled gradual release over 7 d. Importantly, lower pH (pH 5.5-6.0) allowed accelerated RTX release (Fig. 1c) , which facilitated quicker release of RTX in the lower-pH tumour microenvironment 34, 35 than in the bloodstream or healthy tissues.
Next, we examined the kinetics of RTX released from nanocapsules with 50% PLA-PEG-PLA crosslinker in B6 mice (Fig. 1d,e ). Mice were injected with a single intravenous dose of either n-RTX or native RTX. Except for day 1, where RTX was slightly lower in the n-RTX group, there were comparable levels in plasma through day 28. In contrast, eight-to tenfold enhancements of free RTX levels were observed in the CNS and brain tissue when delivered by n-RTX relative to native RTX. Mice treated with n-RTX had detectable levels of RTX in the CNS and brain for up to 4 weeks. Similar results were also confirmed in rats (data not shown). Immunohistochemical staining of rat brains treated with n-RTX showed normal microglia and astrocyte morphology ( Supplementary Fig. 4 ) 36, 37 . No significant elevation of ionized calcium-binding adaptor molecule 1 (Iba1) in microglial cells, nor glial fibrillary acidic proteins (GFAP) in the astrocytes of rat brains treated with nanocapsules, were observed compared with untreated control animals ( Supplementary Fig. 4b,c) . These results provide proof of concept for the penetration, release, maintenance and safety of mAb nanocapsules in both plasma and the CNS.
Encapsulated RTX effectively controls CNS lymphoma formation. Next, we compared the anti-lymphoma efficacies of native RTX and n-RTX in a xenograft murine model. First, we established a human NHL xenograft murine model that can consistently form CNS lymphomas with 2F7 cells-a cell line derived from acquired immune deficiency syndrome-associated B-cell NHL 38 . These 2F7 cells were marked with an mStrawberry reporter gene by a lentiviral vector. Individual subclones were tested for their ability to metastasize into the CNS. Two out of ten sublines formed CNS lymphomas within 7 weeks after intraperitoneal injection. Lymphoma cells were isolated from the brain of one of these sublines and readapted to cell culture. The resulting cell line, termed '2F7-BR44' , formed CNS lymphomas in 100% of mice within 7 weeks following ) in 100 µl Hank's balanced salt solution were injected into the non-obese diabetic (NOD)-SCID gamma (NSG) mice via the tail vein. Five days after injection, mice were randomly separated into three groups: no treatment (n = 3), native RTX or n-RTX treatment (n = 4). Native RTX or n-RTX was injected via the retro-orbital vein at 4 mg kg
a, Kaplan-Meier survival curves of the mice in each group were plotted relative to the number of weeks after 2F7-BR44 cell injection. Statistical significance was determined by log-rank test. b, Tissue distributions of 2F7-BR44 cells in the blood, perfused bone marrow and brain were analysed by flow cytometry at the endpoints. Data are shown as means ± s.d. of biological triplicates (no treatment) or quadruplicates (RTX or n-RTX). Statistical significance was calculated, compared with the no-treatment group, by one-tailed unpaired t-test with Welch's correction. Note that the apparent higher tumour burden in the brain for the native RTX group compared with the no-treatment group was due to the 1-week-longer duration of the native RTX group versus the no-treatment group (the mice in the no-treatment group were euthanized 1 week earlier due to massive systemic tumour growth). Fig. 5a ) or 1-2 weeks following tail vein injection of 2 × 10 6 cells ( Supplementary  Fig. 5b ). These 2F7-BR44 cells maintained expression of four pan-B-cell markers (CD19, CD20, CD22 and CXCR5) at levels comparable to the parental 2F7 cells (Supplementary Fig. 6a ). The cells were sensitive to apoptosis mediated by RTX, comparable
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to the parental cell line, and were also sensitive to complement in vitro ( Supplementary Fig. 6b,c) .
Lymphoma burdens and therapeutic efficacies were quantified by evaluating the percentage of mStrawberry + 2F7-BR44 cells in different tissues. CNS metastases generally arise later than those in systemic organs; without treatment, animals usually die from systemic complications. Mice with lymphoma show apparent signs of lymphoma burden, such as weight loss, pale skin, anaemia and decreased activity. Once the lymphoma burden in the CNS increases up to ~15%, as quantified by the percentage of mStrawberry + in the single-cell fraction obtained from whole brain tissues following perfusion, mice show hindleg paralysis. Native RTX treatment significantly extended the survival of mice engrafted with 2F7-BR44 cells ( Supplementary  Fig. 7b ), and efficiently reduced the lymphoma burden in the bone ). Five days after the injection, mice were randomly separated into three groups (n = 5): native RTX, n-RTX or n-RTX
CXCL13
. Each form of RTX was administered via retro-orbital injection at 4 mg kg
Kaplan-Meier survival curves of the mice in each group were plotted relative to the number of weeks after 2F7-BR44 cell injection (a). Statistical significance was determined by log-rank test. The percentages of 2F7-BR44 cells in the brain were analysed by flow cytometry at endpoints following cardiac perfusion (b). Statistical significance, compared with the native RTX group, was determined by one-tailed unpaired t-test with Welch's correction. Data are shown as means ± s.d. of biological quintuplicates. c,d, The localization of goldlabelled n-RTX (GDMA) , with or without CXCL13 conjugation, was analysed in the brains of 2F7-BR44 xenograft NSG mice (n = 3) 3 weeks after xenograft. One day after the administration of gold-labelled n-RTX (GDMA) or n-RTX (GDMA) CXCL13 via retro-orbital injection, brain tissue samples were processed for immunohistochemical analysis (c). Gold nanoparticles (black depositions) in paraffin sections were analysed following silver enhancement. 2F7-BR44 cells were stained with anti-human Ku80 antibody and rhodamine red-X anti-rabbit IgG. The nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPI). Asterisks indicate the tumour sites. White dashed curves illustrate the boundaries of tumour-normal parenchyma. Scale bar, 25 μm. The average counts of gold-labelled n-RTX (GDMA) or n-RTX (GDMA) CXCL13 per mm 2 from randomly picked five tumour site locations and five normal tissue locations in 15 slides obtained from three xenograft mice in each group (total counts from samples administered with n-RTX (GDMA) or n-RTX (GDMA) CXCL13 are approximately 11,000, respectively) were quantified using ImageJ. Data are shown as means ± s.d. of five random representatives from biological triplicates (d). Statistical significance, compared with normal tissue, was determined by one-tailed unpaired t-test with Welch's correction. e, Representative images of intraocular lymphoma and lymphoma surrounding the kidney in each group.
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Next, we compared the efficacy of native RTX versus n-RTX in controlling lymphoma formation in the brain. n-RTX improved the therapeutic efficacy of RTX against CNS metastases in the NHL murine model; in contrast, untreated animals required euthanization at week 3.5-4 due to severe anaemia (Fig. 2a) . Treatment significantly improved mouse life spans: native RTX-treated mice survived up to week 5, whereas half of the n-RTX-treated mice showed no symptoms of lymphoma formation in the brain until the end time points (week 5.5). Both native RTX and n-RTX capably suppressed lymphoma formation in the bone marrow. In contrast, n-RTX significantly reduced the lymphoma burden in the brain, whereas native RTX had no effect, despite effective systemic control (Fig. 2b) . The correlation between controlled lymphoma growth and heightened RTX concentration illustrated by these results further shows that RTX delivered via nanocapsules exerts control over CNS metastases.
Nanocapsules conjugated with CXCL13 can target lymphoma cells by binding to CXCR5. Ligands can be readily conjugated to the surface of nanocapsules to redirect them to specific targets; thus, targeting nanocapsules to lymphoma cells is predicted to increase RTX concentrations at the site of the lymphoma, enhancing the potency and specificity of activity. To demonstrate the potential of ligand-mediated lymphoma targeting, we selected CXCL13 (a chemokine belonging to the CXC family that interacts with CXCR5 (a receptor expressed on mature B cells 39, 40 ) and is associated with NHLs of B-cell origin [41] [42] [43] ). In malignancies, CXCL13 has suspected involvement in the metastasis of lymphoma cells 44, 45 ; therefore, to ensure accurate modelling of the metastatic environment, we evaluated CXCR5 expression in 2F7-BR44 cells and confirmed that they showed a similar level of CXCR5 expression to that of parental 2F7 cells (Supplementary Fig. 6a ). We then conjugated CXCL13 to the surface of nanocapsules at a molar ratio of approximately 1:1 (Supplementary Fig. 8 ; n-RTX
CXCL13
). This conjugation did not induce significant changes in either the particle size or the surface charge of n-RTX ( Supplementary Fig. 9a,b) .
To evaluate the binding of CXCL13-conjugated nanocapsules, enhanced green fluorescent protein (EGFP) was used as a model protein for nanocapsule synthesis with GDMA crosslinkers, which are slowly hydrolysable under physiological conditions (n-EGFP (GDMA) and n-EGFP (GDMA)
). We found that CXCL13 conjugation improved the specific binding of nanocapsules on 2F7-BR44 cells ( Fig. 3b; 2F7 ) while minimizing non-specific binding on non-targeted cells ( Fig. 3b; Jurkat) . This specific binding of n-EGFP (GDMA) CXCL13 on 2F7-BR44 cells was further confirmed by flow cytometry (Fig. 3c) . Importantly, CXCL13 conjugation did not change the surface properties of MPC nanocapsules, maintaining resistance to cellular uptake. Similar to n-RTX (GDMA) , n-RTX (GDMA) CXCL13 bound to 2F7-BR44 cells but was not internalized (Supplementary Fig. 10 ). Biodistribution data showed that both n-RTX (GDMA) and n-RTX (GDMA) CXCL13 systemically distributed in mice (Fig. 3d) , were delivered with uniform efficiency within the brain, and exhibited decreased accumulation in the liver, kidney and lung-tissues known to show non-specific accumulation of antibodies (Fig. 3e,f) . Next, we demonstrated the enhanced effectiveness of n-RTX conjugated with CXCL13 (n-RTX CXCL13 ) in controlling lymphoma growth in a xenograft murine model. Compared with native RTX, there was significant improvement in the kinetics of RTX delivery released from both n-RTX and n-RTX CXCL13 into the CSF and brain; minimal differences were noted between the two kinds of nanocapsules ( Supplementary Fig. 11a ). Moreover, there were no clear liver or kidney toxicities over 4 weeks of nanocapsule treatment (Supplementary Fig. 11b) . Importantly, compared with native RTXand n-RTX-treated animals, mice treated with n-RTX CXCL13 showed improved survival (Fig. 4a) and minimal CNS lymphoma formation until the end time points (Fig. 4b) . Greater amounts of n-RTX CXCL13 were observed in areas of lymphoma growth (Fig. 4c,d ), indicating that n-RTX CXCL13 preferentially locates with 2F7-BR44 lymphoma in the brain. Besides lymphomas in the brain, renal lymphoma and intraocular lymphoma were also observed in this NHL murine model. Unlike native RTX treatment, intraocular lymphoma was prevented by treatment with n-RTX; however, nodules still formed on the kidneys (Fig. 4e) . n-RTX CXCL13 showed clear co-localization with 2F7-BR44 cells in the kidneys (Supplementary Fig. 12 ), and exerted superior anti-lymphoma activity in both locations compared with native RTX or n-RTX (Fig. 4e ).
Nanocapsules conjugated with CXCL13 improved therapeutic efficacy at different stages of lymphoma progression. To facilitate longitudinal analysis of lymphoma location and progression, the NHL mouse model was further adapted for optical imaging by marking 2F7-BR44 cells with a lentiviral vector expressing firefly luciferase (2F7-BR44-Luc). Following injection of d-luciferin, the substrate of luciferase, in vivo distributions and growth of 2F7-BR44-Luc cells were monitored by in vivo bioluminescence imaging over time (Supplementary Fig. 13 ). Bioluminescence imaging in the NHL xenograft murine model indicated that 2F7-BR44 cells initially migrated into the lungs after tail vein injection, followed by redistribution to the CNS (brain and spinal cord) and bone marrow from the sternum and femur within the first week. At week 2, the signal intensity from lymphomas in the brain, spinal cord, sternum, femur and kidneys increased.
Based on the kinetics of lymphoma formation, we conducted studies in which treatment was initiated after lymphoma formation. Mice were treated with native RTX or n-RTX CXCL13 at different times: week 1 (group I) and week 2 (group II) post-injection of 2F7-BR44-Luc cells. Treatment with n-RTX CXCL13 in both groups resulted in significant control of the lymphoma burden relative to native RTX treatment, as measured by bioluminescence in a defined area (Fig. 5a,b) . The survival of lymphoma-bearing mice was significantly extended by 1-2 weeks as a result of n-RTX CXCL13 treatment compared with native RTX treatment in both groups I and II (Fig. 5c,d) . To quantify the difference in therapeutic CXCL13 groups were monitored weekly using bioluminescence imaging on an IVIS Lumina II In Vivo Imaging system in group I (a) and group II (b). Boxes containing a red X represent deceased mice. Sensitivity settings were adjusted at each time point to maintain 500-5,000 counts per pixel and assigned the same colour scale for both groups. c,d, Kaplan-Meier survival curves of the mice in group I (c) and group II (d) were plotted relative to the number of weeks after 2F7-BR44-Luc cell injection. e-h, BLI values in the whole body (e and f) and head area (g and h) were compared between mice treated with native RTX and those treated with n-RTX CXCL13 in group I (e and g) and group II (f and h). Data are shown as means ± s.d. of biological quadruplicates. Statistical significance, compared with the native RTX group, was determined by one-tailed unpaired t-test with Welch's correction. Red arrows show the treatment time in each figure.
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efficacy between native RTX and n-RTX CXCL13 , the bioluminescence intensity (BLI) from 2F7-BR44-Luc cells in the whole body was compared every week after treatment (Fig. 5e,f) . In group I, the whole-body therapeutic efficacy was similar in the first week post-treatment across both treatment types but was significantly improved by n-RTX CXCL13 later, suggesting more effective control of the lymphoma burden by n-RTX CXCL13 . In group II, there was a significantly greater effect of n-RTX CXCL13 treatment, but the effect was less great than in mice treated in group I. To assess the impact on CNS lymphomas, BLIs from the head area were quantified c d Articles NAtuRE BiomEdiCAL ENgiNEERiNg (Fig. 5g,h ). Treatment with n-RTX CXCL13 notably slowed and controlled the CNS lymphoma burden in both groups. In group II, where lymphomas had already formed in the CNS before treatment, all mice with n-RTX CXCL13 showed a decrease in the lymphoma burden at 1 week following treatment.
Nanocapsules conjugated with CXCL13 eliminated lymphoma in xenograft humanized BLT mice. The above NHL xenograft murine model uses immunodeficient mice in which the death of 2F7-BR44-Luc cells is likely to be primarily-if not exclusivelycaused by the induction of apoptosis. RTX is known to induce anti-lymphoma killing through multiple mechanisms in addition to apoptosis, including ADCC and CDC 26 . Thus, the efficacy of RTX against CNS lymphomas in the NHL xenograft model is highly limited 46 . We further evaluated n-RTX CXCL13 in a humanized BLT murine model wherein human T cells, B cells, natural killer cells and macrophages reconstitute; of these populations, both natural killer cells and macrophages can induce ADCC. Humanized BLT mice develop notably human natural killer and macrophage populations in tissues, including the brain [47] [48] [49] [50] . Consistent with a published study 51 , we found substantial macrophage repopulation in the brains of these mice (data not shown). Humanized BLT mice were treated with native RTX or n-RTX CXCL13 at week 1 post-injection of 2F7-BR44-Luc cells and monitored for lymphoma growth for 12 weeks. An anti-human epidermal growth factor receptor 2 monoclonal antibody (herceptin, HER) and HER nanocapsules ) were injected into humanized BLT mice generated from two independent donors (donors I and II) via the tail vein. Mice were randomly separated into two groups for treatment with native RTX or n-RTX CXCL13 at week 1 after the injection. Each form of RTX was administered via the retro-orbital vein at 4 mg kg
The tumour progression status was tracked weekly using bioluminescence imaging on an IVIS Lumina II In Vivo Imaging System. a, Biodistribution of 2F7-BR44-Luc cells in humanized mice treated with native RTX or n-RTX CXCL13 at week 1, as visualized by luciferase bioimaging. Sensitivity settings were adjusted at each time point to maintain 250-5,000 counts per pixel and assigned the same colour scale for all treatment groups. b, Kaplan-Meier survival curves of the mice were plotted relative to the number of weeks after injection. Necropsies were performed at the end of the experiment (week 13). Statistical significance was determined by log-rank test. c, Percentages of 2F7-BR44-Luc cells in tissues were assessed by flow cytometry following cardiac perfusion at the endpoints. Statistical significance, compared with the native RTX group, was determined by one-tailed unpaired t-test with Welch's correction.
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(n-HER CXCL13 ) were included as negative controls. Native RTX treatment showed effective therapeutic efficacy throughout the body except in the brain, which resulted in paralysis on weeks 4-8; additionally, neither native HER nor n-HER CXCL13 treatment showed any therapeutic effect (Fig. 6a) . In contrast, n-RTX CXCL13 completely eliminated lymphomas in mice, and initiated regression of CNS lymphomas, with no relapse observed (even at the endpoint at week 13). The survival of lymphoma-bearing mice was significantly extended by n-RTX CXCL13 treatment (Fig. 6b) . The clearance of lymphomas was confirmed by flow cytometry of tissues (Fig. 6c) .
We demonstrate that a single-course treatment of RTX encapsulated within an MPC-based nanocapsule designed to administer mAbs by timed release results in CNS RTX concentrations up to tenfold higher than native antibody and yields detectable levels for at least 4 weeks in a murine model. Using an NHL xenograft murine model, better penetration into the CNS allows control of CNS lymphoma formation. Three basic components were tuned to increase the anti-lymphoma effects of RTX: (1) a polymer shell that allows for longer systemic circulation and CNS penetration; (2) crosslinkers that stabilize the polymer shell and release mAbs through timed hydrolysis; and (3) CXCL13 conjugated to the surface, enabling targeting to CXCR5-expressing lymphoma cells. CNS penetration of the nanocapsules appears to be mediated by the binding of choline and acetylcholine analogues of the nanocapsule polymer shell to choline transporters and acetylcholine receptors 52 . Enhanced RTX levels in the CNS could act to control local lymphoma growth through various effector mechanisms. Both CDC and ADCC function in the CNS [53] [54] [55] [56] , but are probably limited due to low antibody levels. In the non-obese diabetic (NOD)-SCID gamma (NSG) xenograft murine model, the induction of apoptosis is likely to be the major mechanism for lymphoma cell elimination since complement components are absent; it is unclear whether murine microglia may contribute to ADCC activity 54 . With limited effector functions, only partial control was achieved in xenografted NSG mice. By repeating studies in humanized BLT mice wherein human macrophages and natural killer cells differentiate, we demonstrated the complete elimination of lymphomas both systemically and in the CNS. We suspect that the differences between these two murine models exist due to the presence of ADCC in the humanized BLT mice, which is absent in the standard xenograft model using NSG mice. Future studies will better elucidate the mechanisms responsible for lymphoma control and clearance.
Outlook
The strategy described here should be applicable to other therapeutic mAbs wherein CNS penetration is limited. For example, breast cancer patients under systemic HER therapy often relapse with CNS metastases that are resistant to mAb therapy 7, 57 . By bypassing the BBB through intrathecal or intraventricular administration, mAb therapy for lymphoma and breast cancer has shown some effectiveness against CNS metastases 7, 58 . Our results suggest a potential non-invasive alternative treatment of CNS lymphomas as well as a potential prophylactic use of the nanocapsules against CNS metastases. Since the biodistribution of mAbs is conferred by the nanocapsules, not the cargo, any mAb (or protein) could be used. Anti-phosphorylcholine autoantibodies have been reported in mice 59 and humans 60 , and could potentially affect the in vivo dynamics of nanocapsules generated with MPC, although we do not observe more rapid clearance relative to native mAbs. We anticipate that further studies on the biodistribution and optimization of formulations through the engineering of polymers, crosslinkers and targeting ligands will further improve CNS delivery and therapeutic efficacy for CNS diseases.
Methods
Synthesis of nanocapsules. Nanocapsules were synthesized with optimized modification for antibodies based on our previous reports 31 . Proteins (RTX or EGFP) were encapsulated via in situ polymerization at room temperature using MPC as the monomer, PLA-PEG-PLA and/or GDMA as the crosslinker, and ammonium persulfate and tetramethylethylenediamine as the initiator. Synthesized nanocapsules were dialysed against phosphate buffered saline (PBS) and purified by passage through a hydrophobic interaction column (Phenyl-Sepharose 4BCL). Detailed parameters, procedures and characterization of the synthesis are provided in the Supplementary Information.
Biodistribution studies. Biodistribution of native RTX and n-RTX was determined by monitoring the free RTX concentration in animal body fluids and perfused tissue homogenates. Briefly, C57BL/6 mice were randomly divided into two groups and injected retro-orbitally at a dose of 20 mg kg −1 mouse −1 (which has been reported as effective in an NHL xenograft murine model 61 ). CSF was collected from a mouse under anaesthesia by ketamine and xylazine (100 mg kg −1 each). After CSF collection, this mouse was perfused with cold PBS and euthanized, and organs were harvested. All perfused tissues were homogenized by vortexing with ceramic beads in PBS containing protease inhibitor cocktail.
NHL mouse model with CNS metastases. Animal research described in the study was approved by the University of California, Los Angeles' Chancellor's Animal Research Committee (Institutional Animal Care and Use Committee), and was conducted in accordance with guidelines for the housing and care of laboratory animals of the National Institutes of Health and Association for Assessment and Accreditation of Laboratory Animal Care International. 2F7 cells were first marked with a fluorescent reporter gene by a lentiviral vector expressing mStrawberry. The 2F7 cells were then subcloned and tested individually for their ability to metastasize into the CNS. We selected clone 44 out of ten clones, which showed stable brain metastatic ability. An NSG mouse received 2 × 10 6 mStrawberry + 2F7 clone 44 cells via intraperitoneal injection and showed brain metastasis 7 weeks post-injection (see Supplementary Fig. 5a ). Lymphoma cells were isolated from the brain metastatic site and adapted to cell culture to establish the 2F7-BR44 cell line. Some 2 × 10 6 of 2F7-BR44 cells were injected into NSG mice via the lateral tail vein to establish an NHL xenograft murine model with CNS metastases.
MAb detection by ELISA. The concentration of RTX in animal body fluids (CSF and plasma) and tissue homogenates was measured by ELISA against RTX. 96-well plates were coated with 1 μg ml −1 anti-RTX antibody (diluted in sodium carbonate-bicarbonate buffer), followed by blocking with 1% bovine serum albumin/PBS for 2 h at room temperature. Diluted RTX in PBST (0.1% Tween 20/PBS) from 0-500 ng ml −1 were then added and incubated for 1 h at room temperature to obtain calibration curves. Animal body fluids and tissue homogenates containing encapsulated RTX in non-degradable nanocapsules were treated with 100 mM sodium acetate buffer (pH 5.4) at 4 °C overnight, then used for ELISA measurement. Free RTX released from n-RTX was directly measured with animal body fluids and tissue homogenates. All animal samples were added to the well and incubated for 1 h at room temperature. After washing five times with PBST, peroxidase-conjugated anti-human Fc antibody was added and incubated for an additional 1 h at room temperature. The substrate 3,3′,5,5′-tetramethylbenzidine solution was added and incubated until the appropriate colour had developed. The reaction was stopped, and absorbance at 450 nm was measured with a microplate reader.
Anti-lymphoma efficacy of RTX in the NHL xenograft murine model with CNS metastases. 2F7-BR44 cells (2 × 10 6 animal −1 ) were injected into NSG mice via the tail vein. Five days after 2F7-BR44 cell injection (unless otherwise stated), mice were treated with a single course of native RTX, n-RTX or n-RTX CXCL13 via retro-orbital vein injection (4 mg kg
Mice were sacrificed when in a critical condition due to the lymphoma burden or at the end time points predetermined in the experiment design. The mice were perfused with cold PBS and euthanized, and organs were harvested for single-cell isolation from tissues. Cells from target tissues were stained with anti-human CD45 and CD19, then analysed by flow cytometry.
In vivo imaging to monitor lymphoma progression. 2F7-BR44 cells were gene marked with a lentiviral vector expressing firefly luciferase, then luciferaseexpressing cells were selected by 1 week of Zeocin treatment (200 µg ml ) were injected into NSG mice or BLT humanized mice via the tail vein. Humanized mice were prepared as previously described, with modifications [62] [63] [64] . Human foetal tissue was purchased from Advanced Bioscience Resources without identifying information, which did not require Institutional Review Board approval for its use. Six-week-old NSG mice were administered busulfan (35 mg kg The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
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Sample size
Sample sizes for the in vivo experiments were estimated on the basis of prior experience with this mouse model. The number of mice assigned to each arm was selected to provide sufficient statistical power to discern significant differences in tumour control and overall survival. The sample size for the humanized mice was limited by the availability of human fetal tissues. For biodistribution experiments in rats, each group had 3 rats; for biodistribution experiments in mice, each group had 3 mice; for antitumor experiments in the xenograft mouse model with native and nano-encapsulated rituximab, each group had 4 mice; for antitumor experiments in the xenograft mouse model with native and ligand-conjugated nano-encapsulated rituximab, each group had 6 mice; for the humanized mouse experiment, each group used 2 humanized mice.
Data exclusions No data were excluded.
Replication
All experiments were reproduced to reliably. In vivo PK and tissue distribution studies were repeated twice and also reproduced with other antibodies. Therapeutic efficacy studies were repeated twice. The humanized mouse studies were repeated with human cells from two donors.
Randomization Rat and mice were randomly allocated into each group by matching average weight in the biodistribution experiments and antitumor experiments; mice (both NSG and humanized mice) were randomly allocated into each group by matching average luciferase intensity from lymphoma in the antitumour experiments monitored with bioimaging.
Blinding
Data collection and analyses of flow cytometry and bioimaging were blinded.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. The primary anti-rituximab antibody (Clone MB2A4, #MCA2260) for ELISA was purchased from Bio-Rad Laboratories (Hercules, CA). The secondary antibody for ELISA detection (goat anti-Human IgG Fc cross-adsorbed secondary antibody, HRP, #A18823) was purchased from ThermoFisher Scientific and used with 1:1000 dilution. For flow cytometry, anti-human CD19 (Clone HIB19, #302211 and #302233), anti-human CD20 (Clone 2H7,#302329), anti-human CD22 (Clone HIB22,#302516), anti-human CD185(CXCR5) (Clone J252D4, #356935), and recombinant CXCL13 (#583908) were purchased from BioLegend (San Diego, CA) and followed the instruction for use. The antibody for IHC, anti-glial fibrillary acidic protein (GFAP) (prediluted,clone GA-5) and anti-ionized calcium binding adaptor molecule 1 (Iba1,#MABN92, with dilution of 1:100) antibodies were obtained from Biocare Medical (Pacheco, CA) and EMD Millipore (Darmstadt, Germany),respectively. Anti-Ku80 antibody (clone C48E7, #2180) from Cell Signaling Technology (Danvers, MA) and rhodamine red-X anti-rabbit IgG (#711-295-152) from Jackson ImmunoResearch (West Grove, PA) were used for detection of 2F7-BR44 cells in the brain with 1:100 and 1:250 dilution, respectively. 4'.6-diamidino-2-phenylindole (DAPI) was purchased from Invitrogen and used with 300 nm concentration.
Validation
Anti-rituximab (#MAC2260): Specificity/sensitivity:Rat anti-rituximab antibody (clone MB2A4) recognizes the monoclonal
